# Halda Therapeutics

Source: https://onco.cc/companies/halda-therapeutics/  
OnCo record `halda-therapeutics` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Halda Therapeutics invented a new kind of oral cancer drug that links a protein found only in tumour cells to a protein cells need to survive, killing the cancer cell. Johnson & Johnson bought the company for 3.05 billion US dollars in 2025.

## Summary

Halda Therapeutics was a New Haven, Connecticut clinical-stage biotechnology company built on its Regulated Induced Proximity Targeting Chimera (RIPTAC) platform: heterobifunctional oral molecules that bring a tumour-specific protein together with a protein essential for cell survival, producing a hold-and-kill mechanism intended to overcome resistance to existing targeted therapies. Its lead candidate, HLD-0915, is a once-daily oral therapy in clinical development for prostate cancer, and the platform is being applied to other solid tumours. SEC Form D filings show about 41 million US dollars sold in 2021 and roughly 150 million US dollars sold across two 2024 offerings. Johnson & Johnson completed its acquisition of Halda for 3.05 billion US dollars in cash on 29 December 2025; the Halda website now redirects to J&J Innovative Medicine.

## Fields

- Kind: Company
- Last checked: 2026-09-10
- HQ: New Haven, CT
- Type: biotech
- Website: https://www.haldatx.com/

## Notes

- haldatx.com redirects to a J&J page that showed a site-maintenance notice, so no original company page was available. The 2024 Form D offerings are widely reported as the Series B but that label was not verified. HLD-0915's clinical phase was not stated in the fetched release beyond 'clinical-stage'.

## Sources

- Official website: https://www.haldatx.com/
- J&J completion press release: https://www.jnj.com/media-center/press-releases/johnson-johnson-completes-acquisition-of-halda-therapeutics-and-its-novel-platform-to-revolutionize-cancer-treatment-and-enable-next-generation-oral-therapies
- J&J Q4 2025 results referencing the acquisition (SEC exhibit): https://www.sec.gov/Archives/edgar/data/200406/000020040626000002/a2025q4exhibit991.htm

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- companies: [Johnson & Johnson](https://onco.cc/companies/johnson-johnson/), [Vida Ventures](https://onco.cc/companies/vida-ventures/)

---
JSON: https://onco.cc/api/v1/entities/halda-therapeutics.json